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Abstract
Background—Epigenetic disturbances are crucial in cancer initiation, potentially with 
pleiotropic effects, and may be influenced by the genetic background.
Methods—In a subsets (ASSET) meta-analytic approach, we investigated associations of genetic 
variants related to epigenetic mechanisms with risks of breast, lung, colorectal, ovarian and 
prostate carcinomas using 51,724 cases and 52,001 controls. False-discovery-rate corrected p-
values (q-values < 0.05) were considered statistically significant.
Results—Among 162,887 imputed or genotyped variants in 555 candidate genes, SNPs in eight 
genes were associated with risk of more than one cancer type. For example, variants in BABAM1 
were confirmed as a susceptibility locus for squamous cell lung, overall breast, ER-negative 
breast, overall prostate, overall and serous ovarian cancer; the most significant variant was 
rs4808076 (odds ratio (OR)=1.14, 95% confidence interval (CI)=1.10–1.19, q=6.87*10−5). DPF1 
rs12611084 was inversely associated with ER-negative breast, endometrioid ovarian, overall and 
aggressive prostate cancer risk (OR=0.93, 95% CI=0.91–0.96, q=0.005). Variants in L3MBTL3 
were associated with colorectal, overall breast, estrogen receptor (ER)-negative breast, clear cell 
ovarian, and overall and aggressive prostate cancer risk (e.g. rs9388766: OR=1.06, 95% CI=1.03–
1.08, q= 0.02). Variants in TET2 were significantly associated with overall breast, overall prostate, 
overall ovarian and endometrioid ovarian cancer risk, rs62331150 showing bidirectional effects. 
Analyses of sub-pathways did not reveal gene subsets that contributed disproportionately to 
susceptibility.
Conclusion—Functional and correlative studies are now needed to elucidate the potential links 
between germline genotype, epigenetic function, and cancer etiology.
Impact—This approach provides novel insight into possible pleiotropic effects of genes involved 
in epigenetic processes.
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INTRODUCTION
Genetic and epigenetic alterations are hallmarks of cancer initiation and progression and can 
influence each other to work cooperatively (1). Dysfunction of epigenetic processes, such as 
DNA methylation, chromatin remodeling and covalent histone modifications can be as 
important in carcinogenesis as the change of the genetic material itself (2). Since the first 
studies that described the global hypomethylation of cancer genomes and the 
hypermethylation of the promoter sequence of mainly tumor suppressor genes, several “pan-
cancer” DNA methylation patterns (patterns across multiple cancer types) have been 
identified (reviewed in (3)). The CpG island methylator phenotype (CIMP) was first 
described in colorectal cancer (4) and later similar patterns were observed in several other 
tumor types. Highlighting the interplay between genetic and epigenetic changes, CIMP 
subtypes usually present with characteristic genetic alterations. CIMP-H colorectal cancers 
are frequently characterized by BRAF mutations, while CIMP-L tumors tend to harbor 
KRAS mutations (5). Non-CIMP colorectal cancer, the B-CIMP-negative breast cancer and 
the low methylated tumor group of serous ovarian cancers frequently acquire TP53 
mutations (5–8).
Furthermore, somatic mutations in epigenetic regulatory genes that are either carcinogenic 
driver or passenger mutations are known to exist. Important mutations have been shown for 
example in DNMTs, IDH1, IDH2 and TETs (as important players of DNA methylation), in 
EZH2 and KDM1A (involved in histone modifications) and in ARID1A (participant of 
chromatin remodeling) (reviewed in (2)). In addition, inherited genetic variants related to 
epigenetic regulatory processes were described in association with multiple cancers (9, 10). 
Given the fundamentality of epigenetic processes, germline variants in genes related to 
epigenetic pathways presumably have pleiotropic effects on the initiation of different 
cancers.
As part of the U.S. National Cancer Institute’s Genetic Associations and Mechanisms in 
Oncology (GAME-ON) Network (http://epi.grants.cancer.gov/gameon/), we have previously 
shown the value of cross-cancer analyses in inflammation pathways (11).
An additional value is that our datasets include large numbers of cancer subtypes that were 
not studied in The Cancer Genome Atlas (TCGA). The present study was focused and 
approved by the GAME-ON consortium for the overall analyses of pleiotropy, where we 
aimed to identify cross-cancer associations of epigenetically related polymorphisms that 
advance our understanding of the role of epigenetics in cancer development. Given the 
central role of epigenetic processes in carcinogenesis, germline variants in genes related to 
epigenetic pathways show pleiotropic effects on the initiation of different cancers. 
Consequently, we investigated whether common polymorphisms in epigenetic genes are 
associated with risk of multiple cancer types (breast, colorectal, lung, ovarian and prostate 
cancer) and their subtypes.
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METHODS
Study population
Within the GAME-ON Network, 32 studies from North America and Europe participated in 
this investigation (12–21). Studies included frequency matched cases and controls on at least 
age, and all subjects were of European descent based on ancestry analyses. The study 
characteristics are summarized in Table 1. In total, 51,724 cancer patients (breast, colorectal, 
lung, ovarian and prostate with respective subtypes) and 52,001 controls were included in 
the analysis.
Gene and variant selection, pathway assignment
Genes (n=634) involved in epigenetic processes were identified using GO and GeneCards 
databases by searching for the following keywords: DNA methylation, DNA demethylation, 
histone acetylation, deacetylation, methylation, demethylation, and other histone 
modification, chromatin remodeling, chromatin modification and histones. The recent 
literature was also reviewed. After excluding genes on sex chromosomes and those not 
covered in all cancer sites, 555 genes were included in the analysis, which were categorized 
into one or more of epigenetic sub-pathways (Supplementary Table S1).
We analyzed all single nucleotide polymorphisms (SNPs) residing within 50 kb of the 
largest transcript for each gene (Databases see in Supplementary Table S2). Overall, 162,887 
polymorphisms were included in the final analysis. In the combined dataset, the major 
alleles (according dbSNP) were used as reference alleles.
Statistical analysis
Cancer sites were further divided into subtypes and for each cancer type and subtype, a fixed 
effect meta-analysis was conducted to combine results from individual studies (Table 1). 
This method used log-additive models adjusted for age, European principal components, and 
sex (where appropriate).
The beta values and standard errors for each cancer or cancer subtype were then combined 
using the association analysis based on a subsets (ASSET) meta-analytic approach, which 
allows for disease heterogeneity and potential opposite directions of the same genetic variant 
on different cancer types (22). It searches for the most parsimonious grouping based on the 
test statistics using any of the five cancers or cancer subtypes simultaneously as the outcome 
variables. Overlapping subjects amongst cancer subtypes (e.g. overlapping cases and 
controls between overall lung cancer and its subtypes) and across cancer types (e.g. UK 
ovary and UK breast GWAS both used controls from Welcome Trust Case Control 
Consortium, WTCCC) were accounted for in the covariance matrix when estimating the 
standard errors (11). The resulting p-values were adjusted using false-discovery rate (FDR) 
correction. Results with FDR q<0.05 were considered statistically significant 
(Supplementary Table S3). All association analyses were performed in R (3.2.5).
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Functional annotation
The overall approach of the functional annotation is summarized in Supplementary Fig. S1. 
For each gene with more than five significant SNPs (FDR q<0.05 in the ASSET meta-
analysis), we selected tagSNPs to represent these regions in subsequent analysis. 
Specifically, a linkage disequilibrium (LD) map was prepared using the Haploview 4.2 
software and tagSNPs were identified with the tagger algorithm of Haploview using 
1000Genomes data (release 20130502). Variants with more than two alleles based on 
1000Genomes were excluded from LD mapping. As a result we were able to investigate 
SNPs that were not covered in the original meta-analysis but potentially have functional 
effect on the genes in the region of interest.
To assess if any of the epigenetic sub-pathways shown in Supplementary Table S1 were 
enriched with genes containing significant associations with cancer types or subtypes, 
pathway analyses were conducted using the ALIGATOR algorithm of the SNPath R 
package.
The possible functional annotation of the tagSNPs and the region-representative SNPs 
(functional follow-up (FFU) SNPs) were then assigned using the FunciSNP R/Bioconductor 
package (23). Using the package, we identified all the corresponding SNPs of our tagSNPs 
using 50 kb searching window and r2>=0.8 as a linkage threshold. In the next step, 
FunciSNP package checks if the corresponding SNPs or the tagSNPs show overlap with 
DNA segments with predicted functional importance. To annotate these biofeatures, we used 
the combined genome segmentation assessed by the ENCODE Project Consortium. These 
results represent ChIP-seq data for eight chromatin marks (H3K4me1, H3K4me2, 
H3K4me3, H3K9ac, H3K27ac, H3K27me3, H3K36me3, H4K20me1), RNA Polymerase II 
and the CTCF transcription factor, as well as DNase-seq and FAIRE-seq data. This data is 
processed with ChromHMM and Segway software which segments the genome into seven 
disjoint segments based on their predicted functional role (24). Since the goal of the study 
was to identify those polymorphisms that change the function of the epigenetic related 
genes, we interpreted polymorphisms that overlap with a predicted transcribed region only, 
if they were in the gene of interest. We used the data available on Huvec, H1hesc and 
Gm12878 cell lines. Unfortunately, comprehensive information for the genome 
segmentation track was not available for all cell lines of the respective cancer types. We thus 
decided to use data from normal cell lines. Additionally, an ENCODE Uniform transcription 
factor binding site (TFBS) track was used, that encompasses data for 161 transcription 
factors from 91 cell types. Supplementary Table S4 summarizes the functional annotation of 
all SNPs based on FunciSNP (SNPs that were annotated as not functional are not listed). 
Furthermore, the functionality of the ASSET-identified SNPs as well as their corresponding 
SNPs were annotated using RegulomeDB, version 1.1.
All software packages and databases that were used are listed in Supplementary Table S2.
RESULTS
The results of the original (individual study based) meta-analyses and the ASSET-based risk 
associations are summarized in Figure 1. Ovarian cancer was associated with the largest 
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number of variants (98), followed by prostate (70), lung (50), breast (46) and colorectal (10) 
cancers. Interestingly, all of the endometrioid ovarian cancer specific SNPs also showed an 
association with overall prostate cancer risk. These polymorphisms were mainly located in 
the RUVBL1 gene regions. Variants in the flanking region of MORF4L1 on 15q25 were 
mainly associated with lung and ovarian cancer. Due to the proximity of MORF4L1 to 
CHRNA5, CHRNA3 and CHRNB4 genes and their well-known association with lung 
cancer, we excluded this region from further analysis (25–27). The number of remaining 
SNPs that were associated with lung cancer risk was 35 and with ovarian cancer was 83. 
Furthermore, variants in PHC3 (3q26) were solely associated with risk of overall prostate 
cancer and will not further be discussed.
When combining genes into epigenetic sub-pathways (see above), we observed no 
significant risk association with more than one cancer type or subtype (p values>0.05) 
indicating that all pathways were similarly important for cancer risk.
Overall 99 SNPs in 8 genes (excluding MORF4L1: 84 SNPs in 7 genes) showed significant 
associations (FDR q<0.05) with risk of more than one cancer type (Supplementary Fig. S2. 
A and B). Genes with associated SNPs were: RUVBL1 (3q21), TET2 (4q24), L3MBTL3 
(6q23), HDAC9 (7p21), BRCA2 (13q12), MORF4L1 (15q25), BABAM1 (19p13) and DPF1 
(19q13) (Table 2, Supplementary Fig. S3). Previous GWAS-identified cancer risk 
associations in these and other genes located in these regions are listed in Supplementary 
Table S5.
The most pleiotropic genes were TET2, BABAM1, DPF1and especially L3MBTL3 (Figure 
1, Table 2). Eleven variants in L3MBTL3 were associated with cancer risk, all with 
pleiotropic effects. The highest OR (odds ratio) in this region was 1.06 (rs9388766, 95% CI 
(confidence interval) =1.03–1.08, FDR q= 0.02), which was associated with risk of 
colorectal, overall breast, ESR1 (ER)-negative breast, clear cell ovarian, overall and 
aggressive prostate cancer. L3MBTL3 is a member of the putative Polycomb group (PcG) 
proteins. Two SNPs, rs9375694 and rs6569648, were previously identified as eQTLs 
(expression quantitative trait locus) for L3MBTL3 (RegulomeDB score: 1d and 1f, 
respectively) (28). The variant allele of rs6899976 may also be functionally important, since 
it overlaps with CTCF enriched regions in all cell lines as well as a transcription factor 
binding site. However, this variant has a RegulomeDB score of only 4.
TET2 (tet methylcytosine dioxygenase 2) at 4q24 encodes a protein catalyzing the 
conversion of methylcytosine to 5-hydroxymethylcytosine. Nine variants at this locus were 
significantly associated with risk of at least two cancer types, of which one variant 
(rs6825684) was associated with decreased risk of four cancers or subtypes: colorectal, 
overall prostate, overall and endometrioid ovarian cancer (OR=0.89, 95% CI=0.85–0.93, 
FDR q=0.02) and one polymorphism (rs62331150) showed a bidirectional effect. The 
variant allele of rs62331150 increased the risk of overall breast and serous ovarian cancer 
(OR:1.09, 95% CI: 1.02–1.15, p-value=0.009) and decreased the risk of clear cell ovarian 
and prostate cancer (OR=0.91, 95% CI= 0.87–0.96, p-value=0.0004) with a combined q-
value of 0.04 (Figure 2). Most of the variants were positioned within TET2. The non-
synonymous rs34402524 was predicted to be deleterious (SIFT) and possibly damaging 
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(PolyPhen). Among the ASSET identified and FFU SNPs, further functional annotation 
singled out polymorphisms with a possible functional role. Rs62331150, (RegulomeDB 
score =2b), overlaps with a transcription start site, a transcription factor binding site and an 
enhancer region.
33 variants, all pleiotropic, showed an association with cancer susceptibility in the region 
containing BABAM1, a known ovarian and breast cancer locus. The strongest association 
was observed for rs4808076, which conferred 14% increased risk of ESR1 (ER)-negative 
breast, serous ovarian and squamous cell lung cancer (OR=1.14, 95% CI=1.10–1.19, FDR 
q=6.87*10−5). Five variants decreased the risk of six cancer types and subtypes; overall 
prostate, overall breast, ESR1 (ER)-negative breast, squamous cell lung, overall and serous 
ovarian cancer risk (strongest signal for rs8100241: OR=0.95, 95% CI=0.93–0.97, FDR 
q=1.78*10−3). Besides BABAM1, the captured region (19p13) additionally contains 
ANKLE1, ABHD8 and USHBP (Supplementary Table S5). BABAM1 was selected for its 
involvement in chromatin modifications, namely ubiquitination as part of the BRCA1 A 
complex. The ASSET identified SNPs in this region were in LD with several variants that 
may play an important role in regulatory processes. The most important ones are shown in 
Table 3. Apart from the variants in regulatory regions, five SNPs were in coding sequences. 
Important features of these variants, as well as their SIFT (29) and PolyPhen (30) scores are 
shown in Table 4.
DPF1 is part of the neuron-specific chromatin remodeling complex (nBAF complex). One 
variant (rs12611084) was significantly associated with endometrioid ovarian, ESR1 (ER)-
negative breast, overall and aggressive prostate cancer risk (OR=0.93, 95% CI=0.91–0.96, 
FDR q=0.005) and one variant (rs8100395) additionally with lung adenocarcinoma 
(OR=0.93, 95% CI=0.90–0.96, FDR q=7.2*10−3). Both variants were located upstream of 
DPF1, some were overlapping with other genes in this region, PPP1R14A and SPINT2, and 
were captured by one tagSNP in the FunciSNP analysis. Seven FFU SNPs showed a possible 
functional role, among them rs7250689, which was previously reported to be an eQTL for 
PPP1R14A (28). Based on RegulomeDB, rs8100395 and rs12611084 (both significant in the 
ASSET analysis) likely affect binding, and additionally overlap with enhancer regions as 
well as transcription factor binding sites and, in the case of rs8100395, overlaps with a 
CTCF enriched region.
Overall, 27 polymorphisms in RUVBL1 were associated with risk of prostate and 
endometrioid ovarian cancer, while one SNP was additionally associated with colorectal 
cancer risk. The strongest association was observed for rs144609957 with increased risk of 
prostate and endometrioid ovarian cancer (OR=1.13, 95% CI=1.08–1.19, FDR q=0.01). 
None of the SNPs had reached genome-wide significance in the original meta-analysis. 
RUVBL1 plays a role in chromatin organization. All associated SNPs belonged to the same 
LD block and were captured by one tagging SNP. Further, FunciSNP analysis revealed seven 
variants that overlapped with multiple biofeatures (transcription factor binding site, weak 
enhancer region and promoter flanking region). These variants also had low RegulomeDB 
scores, the lowest being 2b for rs9879865 and rs9879866, variants that likely affect binding.
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DISCUSSION
We performed the first large-scale association study of variants in epigenetic-related genes 
and cancer risk utilizing the extensive genomic data on 51,724 cancer patients and 52,001 
controls and identified eight epigenetic-related genes with pleiotropic effects on cancer risk.
Epigenetic disturbances are common drivers of carcinogenesis, yet, effects of germline 
variants and their potential pleiotropic mechanisms are not well understood. Thus, we 
investigated the risk association of SNPs related to epigenetic processes with multiple 
cancers. Using a subset-based meta-analysis, we were able to account for different subsets of 
cancer types and subtypes even with contrasting risk associations.
The L3MBTL3 gene on 6q26 is a member of the putative Polycomb group (PcG). It contains 
a methyl-lysine reader Malignant Brain Tumor (MBT) domain that is responsible for the 
recognition of the mono- and di-methylated lysines of H3 and H4 histone tails. MBT domain 
proteins are associated with gene expression repression and their dysregulation has been 
shown to contribute to different diseases (31). In our analysis, two variants (rs9375694 and 
rs6569648), which were previously identified as eQTLs, were significantly associated with 
risk of prostate and breast cancer (and their subtypes), and to a lesser extent with risk of 
clear cell ovarian and colorectal cancer (28). Interestingly, previous GWAS identified an 
association of rs6569648 and rs6899976, both hits in our analysis, with height (32) and 
height is associated with risk of several cancers including breast, ovarian, prostate and 
colorectal cancer (33). Our findings suggest the link between height and cancer risk may be 
vis-a-vis altered epigenetic processes, but this requires further investigations.
Several SNPs located in and around TET2 showed significant associations with risk of 
overall prostate, overall ovarian, endometrioid ovarian, overall breast and colorectal cancer. 
Previous studies reported significant associations of variants at the TET2 locus with risk of 
cancer including ovarian and breast cancer (9, 21, 34). A large number of functional variants 
were identified in this region forming multiple pleiotropic linkage blocks that support the 
role of TET2 and its germline variants in the development of multiple cancer types. 
Furthermore, an association between rs62331150 and TET2 gene expression in breast 
normal and tumor tissue was recently shown (9). The bidirectional association of the 
rs62331150 variant allele implies that the effect of TET2 genetic variation may be of a 
different nature for distinct cancers, increasing the risk of breast cancer, but decreasing the 
risk of prostate cancer. Similar associations were observed for a group of highly linked 
polymorphisms, namely rs2007403, rs2047409, rs6533183, rs6839705, rs11097882 and 
rs13147502 confirming previous studies (21, 35); however, with only one statistically 
significant risk direction.
Several functional variants were found at 19p13 with significant associations observed for 
risk of ESR1 (ER)-negative breast cancer, serous ovarian cancer and squamous cell lung 
cancer, but also with overall ovarian, breast and prostate cancer. BABAM1 is involved in 
chromatin modifications (ubiquitination), as part of the BRCA1 complex and regulates the 
retention of BRCA1 at double strand DNA breaks to maintain stability of this complex at the 
sites of DNA damage (36). Previous GWAS associated this region with breast (37) and 
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ovarian cancer (10), with some of the SNPs showing triple-negative breast cancer specificity 
(38). However, to our knowledge we are the first to describe an association with squamous 
cell lung cancer or overall prostate cancer risk. Demonstrating a limitation of our selective 
candidate gene approach, new evidence suggests that nearby 19p13 genes ANKLE1 and/or 
ABHD8, rather than BABAM1, may be the functional drivers in breast and ovarian cancer 
[Lawrenson et al, Nature Communications in press]. The complexity of this region requires 
detailed functional follow up to disentangle the combined effect of individual variants and to 
understand their role in carcinogenesis.
DPF1 is part of the mSWI/SNF (also called BAF) chromatin remodeling complex with a 
central role in carcinogenesis (39). Mutations in DPF1 were seen in solid tumors (7). 
Furthermore, significant overexpression of DPF1 was observed in breast and squamous cell 
lung cancers (40). Our results also support a pleiotropic effect of DFP1 during 
carcinogenesis through potentially functional polymorphisms in this gene. However, as in 
each region of interest, we cannot exclude the potential relevance of the other genes in this 
region (PPP1R14A, SPINT2).
Polymorphisms in 3q21 were previously only observed in association with prostate cancer 
risk (41); however, our analysis has detected additional associations with endometrioid 
ovarian and colorectal cancer risk. RUVBL1 is a member of the INO80 family protein 
remodeling complex. It interacts with MYC and CTNNB1 (β-catenin), participates in many 
signal transduction pathways and is overexpressed in many cancer types (42). We have 
identified several polymorphisms with seemingly strong functional impacts. Interestingly, a 
proportion of endometrioid ovarian and colorectal cancers arise from common etiologies 
associated with hereditary non-polyposis cancer (HNPCC) or Lynch syndrome (43) and also 
show de novo promoter methylation silencing of DNA mismatch repair genes (44) and 
altered β-catenin signaling (45). RUVBL1 may represent novel susceptibility genes that 
further unify endometrioid ovarian and colorectal cancer development.
The major strength of this study is the large sample size of more than 100,000 subjects 
across five cancer types and their subtypes, some of which were not studied in TCGA. In 
addition, by searching the most parsimonious grouping based on the test statistics using any 
of the five cancers or cancer subtypes simultaneously as the outcome variables, the ASSET-
subset-based meta-analysis (1) increased the power to detect associations, which may not 
have been detected in the individual analyses of the five cancer types, (2) allowed estimation 
of associations with opposing effects, and (3) provided new insights into pleiotropy that 
were not observed in the original analyses (22). Further, the overlapping subjects (cases and 
controls) are accounted for during the analysis (11). Finally, our focused approached 
reduced the genome-wide multiple testing burden and allowed for examination of 
functionally grouped subsets of epigenetic-related genes (i.e., sub-pathways). We were thus 
able to confirm established and identify new risk genes, including TET2 and L3MBTL3.
Although the odds ratios that are discovered as pleiotropic across cancer types may be 
considered modest, there is potential clinical significance. First, the ORs for individual 
cancers may be higher than the summary OR. Second, the combination of several SNPs with 
low ORs may become relevant through creation of a risk score, and third, the association of 
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SNPs with disease may be modified and, in some instances, strengthened by environmental 
factors.
While our approach provides interesting insights into the pleiotropic effects of selected 
regions, it is limited with respect to the assignment of the identified predisposing variants to 
genes by chromosomal position rather than the actual cancer-initiating processes. Of note, 
several of the identified pleiotropic associations cannot clearly be linked to the selected 
epigenetic genes, as some of the regions additionally contain genes that were previously 
described for their effect on carcinogenesis.
Further investigations are required to elucidate the functional link between the identified 
pleiotropic variants and their impact on epigenetic processes such as the potential effect of 
TET2 polymorphisms on DNA methylation. Indeed, our pathway-based selection of 
epigenetic-related genes overlooked the subtleties of complex gene networks, and most 
genes are involved in multiple biological processes. Finally, this dataset did not allow for the 
investigation of interactions with other genetic or environmental factors, which are 
undoubtedly of great importance.
In summary, using a unique, large dataset, we identified novel pleiotropic variants in 
epigenetic-related genes that are associated with susceptibility to multiple cancer types and 
subtypes. This study provides the basis for future studies investigating the impact of these 
variants, their causal relationship to epigenetic processes, and the mechanisms leading to 
carcinogenic pleiotropy.
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Figure 1. 
Manhattan plot showing the original meta-analyses (A) and the results of the ASSET-based 
meta-analysis (C) on the selected SNPs available for all studies. Variants with –log10 (p 
values) higher than 20 are not shown. Regions showing significant pleiotropic association in 
the ASSET analysis are marked in green.
Pie charts (B) show the number of variants that were significant in the ASSET analysis. 
Numbers in brackets depict the number of independent risk loci. Each diagram represents a 
gene region and the numbers of SNPs associated with a specific cancer type (in the same 
colors as indicated in the Manhattan plot (A)) are shown. SNPs associated with multiple 
cancer types are counted in each of the respective cancer sections. Overlap is not visualized.
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Figure 2. 
(A) Linkage disequilibrium (LD) plot encompassing the significant SNPs in the TET2 
region. Selected SNPs representing each LD block with respective forest plots are shown for 
(B) rs62331150 representing the single-variant block A; (C) rs17508261representing block 
B1 and B2; and (D) rs2007403 representing block C.
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